Inquiry Basket
Deruxtecan analog is a drug-linker conjugate for antibody-drug conjugate (ADC). Deruxtecan, a topoisomerase I inhibitor, is an exatecan derivative (DX-8951 derivative) with a cleavable pepetide linker and a maleimide group. The maleimide group in Deruxtecan can react with antibody to form antibody-drug conguates (ADC) such as Trastuzumab deruxtecan (DS-8201a), which is a HER2-targeting antibody-drug conjugate. DS-8201a significantly suppressed tumor growth in an immunocompetent mouse model with human HER2-expressing CT26.WT (CT26.WThHER2) cells. DS-8201a is currently in clinical trials.
| Catalog Number | Size | Price | Quantity | ||
|---|---|---|---|---|---|
| BADC-00606 | 5 mg | $649 | Inquiry |
| NCT Number | Condition Or Disease | Phase | Start Date | Sponsor | Status |
|---|---|---|---|---|---|
| NCT04526691 | Advanced or Metastatic NSCLC | Phase 1 | 2021-10-22 | Daiichi Sankyo, Inc. | Recruiting |
| NCT04965766 | Metastatic Breast Cancer | Phase 2 | 2021-07-16 | Gustave Roussy, Cancer Campus, Grand Paris | Recruiting |
| NCT05113251 | Breast Neoplasms | Phase 3 | 2021-11-09 | AstraZeneca | Recruiting |
| NCT04619004 | Non-Small Cell Lung Cancer Metastatic | Phase 2 | 2021-11-15 | Daiichi Sankyo, Inc. | Recruiting |
| NCT04622319 | HER2-Positive Primary Breast Cancer | Phase 3 | 2021-11-05 | Daiichi Sankyo, Inc. | Recruiting |
Deruxtecan, a powerful antibody-drug conjugate (ADC), is designed for targeting and killing cancer cells. Here are some key applications of Deruxtecan:
Targeted Cancer Therapy: Deruxtecan is used in targeted cancer therapy to deliver cytotoxic agents directly to cancer cells while sparing healthy tissues. It is particularly effective in treating HER2-positive breast cancer by binding to the HER2 receptor and releasing its cytotoxic payload. This targeted approach minimizes systemic toxicity and enhances therapeutic efficacy.
Drug Development: Researchers employ Deruxtecan in the development of new cancer treatments, especially for tumors that express specific antigens. By conjugating different cytotoxic drugs to the monoclonal antibody component of Deruxtecan, scientists can create versatile ADCs that target a variety of cancers. This flexibility allows for the design of personalized medicine strategies tailored to individual patient profiles.
Clinical Trials: Deruxtecan is actively used in clinical trials to evaluate its safety and effectiveness in treating various types of cancer, including gastric and lung cancers. These trials are essential for gaining regulatory approval and expanding the therapeutic indications of Deruxtecan. Positive outcomes from these studies can lead to broadened clinical applications and improved patient outcomes.
Resistance Overcoming Strategies: Deruxtecan serves as a promising solution for overcoming resistance to conventional therapies. In cases where tumors have developed resistance to standard chemotherapies, Deruxtecan’s mechanism allows it to circumvent resistance pathways and effectively kill cancer cells. This application is crucial for managing refractory cancers and improving long-term survival rates.
Customer Support
Providing excellent 24/7 customer service and support
Project Management
Offering 100% high-quality services at all stages
Quality Assurance
Ensuring the quality and reliability of products or services
Global Delivery
Ensuring timely delivery of products worldwide
BOC Sciences offers comprehensive services for ADC manufacturing, including antibody modification, linker chemistry, payload conjugation, and formulation development. In particular, our payload-linker customization service offers a convenient and fast raw material channel for many ADC researchers.
BOC Sciences provides one-stop site-specific conjugation services for amino acids, glycans, unnatural amino acids, and short peptide tags. In addition, cysteine conjugation, lysine conjugation, enzymatic conjugation, thio-engineered antibody can also be obtained quickly.
BOC Sciences offers a full range of linkers, including peptide linkers, PEG linkers, click chemistry, PROTAC linkers, non-cleavable linkers, etc. We also provide custom development services for chemically labile linkers and enzymatically cleavable linkers.
